BioPharma Dive January 30, 2025
The two offerings add to an uptick in IPO activity that some in the industry expect will continue throughout this year.
Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced Thursday.
Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, according to BioPharma Dive data. Maze, a maker of kidney disease medicines, priced more than 8.7 million shares at $16 each, exceeding the terms it had set earlier this week.
Metsera shares will trade on the Nasdaq Friday under the symbol...
Today's Sponsors
Today's Sponsor